alvespimycin + trastuzumab + paclitaxel

**alvespimycin + trastuzumab + paclitaxel** is an investigational combination regimen studied for advanced solid tumors, particularly **HER2-positive metastatic breast cancer** refractory to prior HER2-targeted therapy.\n- **Alvespimycin (KOS-1022, 17-DMAG)** is a second-generation small molecule inhibitor of **heat shock protein 90 (Hsp90)**. Hsp90 inhibition disrupts multiple oncogenic signaling pathways, including HER2, leading to tumor cell death and sensitization to other anticancer agents[1][2][4].\n- **Trastuzumab** is a monoclonal antibody that specifically binds to **HER2 (ErbB2)** on tumor cells, inhibiting proliferation and inducing antibody-dependent cellular cytotoxicity[2].\n- **Paclitaxel** is a microtubule-stabilizing chemotherapeutic agent that inhibits mitosis and induces apoptosis in rapidly dividing tumor cells.\nThe triplet regimen was designed to leverage synergistic effects, as Hsp90 inhibition can restore trastuzumab sensitivity and enhance taxane activity[1][4].\nPhase 1 clinical trials examined the safety, tolerability, pharmacokinetics, and early efficacy of this combination in heavily pre-treated patient populations[1][4].

Other names

17-DMAG + trastuzumab + paclitaxel